Breakthrough blood tests that can flag dozens of cancers before symptoms appear are gaining momentum, yet questions remain about accuracy, equity, and how these tools will fit into routine care.

In this episode, Steve talks with Helmy Eltoukhy, co-founder and co-CEO of Guardant Health, a $14 billion publicly-traded precision oncology company. The conversation explores the science behind cell-free DNA, the rise of blood-based cancer screening, and the broader shift toward data-driven diagnostics.

From law school to leading one of healthcare's most successful value-based care companies, Oak Street Health co-founder Mike Pykos shares the story of building, scaling, and ultimately selling his company to CVS for $11 billion.

He reveals the challenges of scaling a new care model, the importance of focusing on outcomes over financials, and what it takes to transform American healthcare.

Join us for many mic-drop moments with recording artist-turned-healthcare-investor D.A. Wallach.